Concepedia

Author

Stéphanie Bot

Idera Pharmaceuticals (United States)

Also Known As

Stephanie Bot, Stéphanie Bot

14

Publications

305

Citations

5

H-Index

16

Concepts

All Affiliations

Idera Pharmaceuticals (United States)Merck & Co., Inc., Rahway, NJ, USA (United States)
SB

About

Stéphanie Bot is an author at Idera Pharmaceuticals (United States) specializing in drug discovery, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

281

2

Natural Sciences

3

3

259

3

Biochemistry

2

2

187

4

Biomolecular Engineering

2

2

42

5

Engineering

1

1

10

Stéphanie Bot

×

5

Publications

302

Citations

5

H-Index

YearCitations

Synthesis and Biological Evaluation of Aryl-phospho-indole as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors

François-René Alexandre, Agnès Amador, Stéphanie Bot,

Journal of Medicinal Chemistry

2010

177

Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor

Cyril B. Dousson, François-René Alexandre, Agnès Amador,

Journal of Medicinal Chemistry

2016

72

The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2′-α-chloro-2′-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors

François-René Alexandre, Eric Badaroux, John P. Bilello,

Bioorganic & Medicinal Chemistry Letters

2017

32

Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor

Jean‐Laurent Paparin, Agnès Amador, Eric Badaroux,

Bioorganic & Medicinal Chemistry Letters

2017

11

Development and Scale-Up of a Manufacturing Route for the Non-nucleoside Reverse Transcriptase Inhibitor GSK2248761A (IDX-899): Synthesis of an Advanced Key Chiral Intermediate

Richard K. Bellingham, Gary T. Borrett, Guillaume Bret,

Organic Process Research & Development

2018

10

Page 1